Supernus Pharmaceuticals Inc
SUPN51.570USD
-0.200-0.39%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.95BMarket Cap
LossP/E TTM
More Details of Supernus Pharmaceuticals Inc Company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Supernus Pharmaceuticals Inc Info
Ticker SymbolSUPN
Company nameSupernus Pharmaceuticals Inc
IPO dateDec 28, 2010
CEOKhattar (Jack A)
Number of employees674
Security typeOrdinary Share
Fiscal year-endDec 28
Address9715 Key West Avenue
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13018382500
Websitehttps://www.supernus.com
Ticker SymbolSUPN
IPO dateDec 28, 2010
CEOKhattar (Jack A)
Company Executives of Supernus Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
10.67K
+10.74%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
901.00
-92.89%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Other
15.60M
9.43%
By RegionUSD
Name
Revenue
Proportion
United States
165.45M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Other
15.60M
9.43%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Other
61.56%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Other
61.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.64%
Investment Advisor/Hedge Fund
25.75%
Hedge Fund
20.25%
Individual Investor
4.29%
Research Firm
3.21%
Pension Fund
1.48%
Venture Capital
1.19%
Bank and Trust
0.63%
Sovereign Wealth Fund
0.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
575
60.19M
104.97%
-3.36M
2025Q2
565
63.61M
113.46%
-2.51M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.01M
14.29%
-191.39K
-2.33%
Jun 30, 2025
The Vanguard Group, Inc.
6.19M
11.04%
+41.36K
+0.67%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.02M
5.39%
+117.48K
+4.05%
Jun 30, 2025
Armistice Capital LLC
4.81M
8.58%
-384.00K
-7.39%
Jun 30, 2025
Nomura Investment Management Business Trust
2.76M
4.93%
+62.46K
+2.31%
Jun 30, 2025
Khattar (Jack A)
2.15M
3.84%
+54.63K
+2.60%
Sep 30, 2025
State Street Investment Management (US)
2.21M
3.94%
+63.21K
+2.95%
Jun 30, 2025
Renaissance Technologies LLC
1.66M
2.95%
+69.60K
+4.39%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
7.48%
iShares Neuroscience and Healthcare ETF
3.83%
Invesco Pharmaceuticals ETF
3.32%
State Street SPDR S&P Pharmaceuticals ETF
3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.21%
Invesco S&P SmallCap Health Care ETF
1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Lattice Hartford Multifactor Small Cap ETF
1.3%
iShares U.S. Pharmaceuticals ETF
1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
0.68%
View more
AdvisorShares Psychedelics ETF
Proportion7.48%
iShares Neuroscience and Healthcare ETF
Proportion3.83%
Invesco Pharmaceuticals ETF
Proportion3.32%
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.21%
Invesco S&P SmallCap Health Care ETF
Proportion1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.63%
Lattice Hartford Multifactor Small Cap ETF
Proportion1.3%
iShares U.S. Pharmaceuticals ETF
Proportion1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.68%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Supernus Pharmaceuticals Inc?
The top five shareholders of Supernus Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A. holds 8.01M shares, accounting for 14.29% of the total shares.
The Vanguard Group, Inc. holds 6.19M shares, accounting for 11.04% of the total shares.
Dimensional Fund Advisors, L.P. holds 3.02M shares, accounting for 5.39% of the total shares.
Armistice Capital LLC holds 4.81M shares, accounting for 8.58% of the total shares.
Nomura Investment Management Business Trust holds 2.76M shares, accounting for 4.93% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.01M shares, accounting for 14.29% of the total shares.
The Vanguard Group, Inc. holds 6.19M shares, accounting for 11.04% of the total shares.
Dimensional Fund Advisors, L.P. holds 3.02M shares, accounting for 5.39% of the total shares.
Armistice Capital LLC holds 4.81M shares, accounting for 8.58% of the total shares.
Nomura Investment Management Business Trust holds 2.76M shares, accounting for 4.93% of the total shares.
What are the top three shareholder types of Supernus Pharmaceuticals Inc?
The top three shareholder types of Supernus Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
How many institutions hold shares of Supernus Pharmaceuticals Inc (SUPN)?
As of 2025Q3, 575 institutions hold shares of Supernus Pharmaceuticals Inc, with a combined market value of approximately 60.19M, accounting for 104.97% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.49%.
What is the biggest source of revenue for Supernus Pharmaceuticals Inc?
In FY2025Q2, the Net product sales-Qelbree business generated the highest revenue for Supernus Pharmaceuticals Inc, amounting to 77.55M and accounting for 46.87% of total revenue.
